1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Terumo Corporation
  6. News
  7. Summary
    4543   JP3546800008


Delayed Japan Exchange  -  02:00 2022-08-17 am EDT
4724.00 JPY   +0.81%
08/12TERUMO : Q&A Session at the Financial Results Briefing for the First Quarter of FYE 3/2023 (PDF 204.5 KB)
08/10TERUMO : Financial Results for the FYE 3/2023(with note) (PDF 1 MB)
08/10Japanese Shares Slide for Second Straight Day; Olympus Logs 33% Jump in Fiscal Q1 Attributable Profit
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Terumo Blood and Cell Technologies and GenCure collaborate to advance cell and gene therapy manufacturing solutions

06/28/2022 | 10:28am EDT

Lakewood, Colorado, US - Terumo Blood and Cell Technologies, a medical technology company specializing in a portfolio of products, software and services for blood component collection, therapeutic apheresis and cellular technologies, today announces it has signed a new collaborative agreement with GenCure, a subsidiary of BioBridge Global, to extend and unify cell and gene therapy manufacturing solutions.

The latest agreement between Terumo Blood and Cell Technologies (Terumo) and BioBridge Global follows a series of long-running activities between the organizations for more than 20 years, including with a number of BioBridge Global's subsidiaries. It is anticipated that this latest agreement will extend into a broader collaboration with the full array of BioBridge Global's subsidiaries. Both parties have signed the new agreement to further combine technologies and expertise to cater to the demand across the cell and gene therapy (CGT) industry for smart systems that are automated and closed. These smart-systems allow for real-time response and refinement to the living therapies being produced inside the systems.

This collaboration will initially utilize expertise from Terumo and GenCure to establish a reference manufacturing center for BioBridge Global. This includes both organizations jointly developing core process and manufacturing operations. The reference site will enable GenCure to deliver a full solution for cell and gene therapy developers. It will be based at GenCure's process development and cGMP manufacturing facility at the VelocityTX campus in San Antonio, Texas, US.

Terumo will contribute a variety of products from its portfolio to allow in-plant optimization of processes and user feedback, along with investment in new products and process utilization. GenCure will leverage its highly developed expertise in Terumo Blood and Cell Technologies' cell collection, cell and gene therapy manufacturing and fill-finish equipment. This will significantly enhance its portfolio for developers requiring process optimization and manufacturing support.

The collaboration is scheduled to last three years and is in two phases. The first phase will enable Terumo to select from its portfolio of automated and closed-cell and gene therapy manufacturing devices and share the range of services offered at GenCure. This combination will help solve the critical industry gaps in manufacturing capacity and operational expertise. The second phase will allow GenCure and other BioBridge Global subsidiaries to use Terumo's data management solutions and value-added services to seamlessly transition between clinical and manufacturing sites by enabling chain-of-custody/identity and consistency of leukapheresis products.

Terumo selected GenCure as a key collaborator that has access under the BioBridge Global umbrella to all of the services needed for cell and gene therapy manufacturing that originates from blood products. These include donor recruitment, cell collections, cell selection and manufacturing facilities and biological testing services. The collaboration allows Terumo to link blood and cell collections with cell and gene therapy manufacturing. There is currently a critical lack of skills and knowledge bridging these areas.

"Despite the rapid evolution of the cell and gene therapy sector, critical challenges such as management between collection, manufacturing sites and logistics still remain unresolved. For over 20 years, Terumo has been working with BioBridge to provide safe, high-quality blood products," said Delara Motlagh, General Manager, Cell Therapy Technologies, Terumo Blood and Cell Technologies. "We are now combining our product portfolios, expertise and management to provide a vital link between cell collection sites and cell and gene therapy manufacturing sites, while addressing capacity and ensuring GMP production. This will provide a route to deliver cutting-edge cell and gene therapies through pursuing new standards of collection and manufacturing, including quality, consistency and demonstrated scalability."

Martin Landon, Chief Executive Officer of BioBridge Global said: "Across the cell and gene therapy sector, collaborations are now proving vital to the rapid development of solutions to a number of key challenges. Our donor-to-patient solutions, which include cell collection, manufacturing and testing, require the best technologies and expertise available in the market. Working with an innovator like Terumo Blood and Cell Technologies will allow us to provide a leading-edge end-to-end solution for cell and gene therapy manufacturing that will be vital to deliver advanced therapies to patients."


About Terumo Blood and Cell Technologies

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.

Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 130 countries across the globe. We have more than 750 granted patents, with more than 150 additionally pending.

We have global headquarters in Lakewood, Colo., US., along with five regional headquarters, seven manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.

About GenCure

GenCure, a subsidiary of San Antonio-based nonprofit BioBridge Global, provides process development and optimization expertise and cGMP manufacturing services for cell and cell-based advanced therapies companies as the anchor tenant for the VelocityTX landmark biotech innovation corridor complex. Working with its sister subsidiaries, GenCure understands and provides support for donor-to-patient services with a foundation in the critical elements related to clinical practice standards, access to source materials, testing services, research and development, and clinical research support. Learn more at GenCure.org.

About BioBridge Global

BioBridge Global (BBG) is a San Antonio, Texas-based 501(c)(3) nonprofit advanced therapies enterprise that offers diverse services through its subsidiaries - South Texas Blood & Tissue, QualTex Laboratories, GenCure and The Blood and Tissue Center Foundation. BBG provides products and services, donor recruitment and sample collection for a wide range of blood and tissue types, processing and manufacturing support, and testing of both donor and finished products for clients in the United States and worldwide. BBG is committed to saving and enhancing lives through the healing power of human cells and tissue. It enables advances in the field of regenerative medicine by providing access to human cells and tissue, testing services and biomanufacturing and clinical trials support. Learn more at BioBridgeGlobal.org.


(C) 2022 M2 COMMUNICATIONS, source M2 PressWIRE

08/12TERUMO : Q&A Session at the Financial Results Briefing for the First Quarter of FYE 3/2023..
08/10TERUMO : Financial Results for the FYE 3/2023(with note) (PDF 1 MB)
08/10Japanese Shares Slide for Second Straight Day; Olympus Logs 33% Jump in Fiscal Q1 Attri..
08/10Terumo's Fiscal Q1 Attributable Profit Falls 20% on Operating Expenses
08/09TRANSCRIPT : Terumo Corporation, Q1 2023 Earnings Call, Aug 09, 2022
08/09TERUMO : Financial Results for the First Quarter of FYE 3/2023 (PDF 1.06 MB)
08/09TERUMO : 1st Quarter Financial Results for FYE 3/2023 (PDF 384.33 KB)
08/09Terumo Corporation Provides Dividend Guidance for the Second Quarter of Year Ending Mar..
08/09Terumo Corporation Provides Dividend Guidance for the Full Year Ending March 31, 2023
08/09Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending M..
More news
Analyst Recommendations on TERUMO CORPORATION
More recommendations
Sales 2023 782 B 5 780 M 5 780 M
Net income 2023 103 B 759 M 759 M
Net Debt 2023 3 725 M 27,5 M 27,5 M
P/E ratio 2023 34,4x
Yield 2023 0,78%
Capitalization 3 570 B 26 377 M 26 377 M
EV / Sales 2023 4,57x
EV / Sales 2024 4,15x
Nbr of Employees 28 294
Free-Float 95,3%
Duration : Period :
Terumo Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TERUMO CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 4 724,00 JPY
Average target price 5 090,71 JPY
Spread / Average Target 7,76%
EPS Revisions
Managers and Directors
Shinjiro Sato Senior Executive Officer
Naoki Muto Chief Financial & Accounting Officer
Toshiaki Takagi Chairman
Katsuya Takeuchi Chief Information Officer & Executive Officer
Kazuhisa Senshu Chief Clinical & Regulatory Affairs Officer
Sector and Competitors
1st jan.Capi. (M$)
MEDTRONIC PLC-7.87%126 639